Celularity Inc - Ordinary Shares - Class A Aktie News

FLORHAM PARK, N.J., May 24, 2024 (GLOBE NEWSWIRE) -- Celularity Inc.  (Nasdaq: CELU) (the “Company”), a regenerative medicine company developing placental-derived allogeneic cell therapies and advanced biomaterial products, announced today that on May 21, 2024, the Company received notification from the Listing Qualifications department of the Nasdaq Stock Market LLC (“Nasdaq”) stating that bec...

Placental T Cells Demonstrated Greater Persistence, Resistance to Exhaustion and Efficacy Compared To Peripheral Blood Mononuclear Cells Placental T Cells Demonstrated Greater Persistence, Resistance to Exhaustion and Efficacy Compared To Peripheral Blood Mononuclear Cells

Event Will Be Hosted On-site and Aired Virtually Highlighting Research, Clinical and Commercial Progress Event Will Be Hosted On-site and Aired Virtually Highlighting Research, Clinical and Commercial Progress

FLORHAM PARK, N.J., April 19, 2024 (GLOBE NEWSWIRE) -- Celularity Inc.  (NASDAQ: CELU) (the “Company”), a regenerative medicine company developing placental-derived allogeneic cell therapies and advanced biomaterial products, announced today that on April 17, 2024, the Company received notification from the Listing Qualifications department of the Nasdaq Stock Market LLC (“Nasdaq”) stating that...

FLORHAM PARK, N.J., April 18, 2024 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”), a regenerative medicine company developing placental-derived allogeneic cell therapies and advanced biomaterial products, today announced that its abstract entitled “Emerging Technologies for the Management and Protection of Tendon Injuries: Decellularized Placental Biomaterials” was accepted b...

CELU Announces Net Sales Trending Ahead of Expectations for 1Q '24; Implements Planned '24 SG&A Reductions & Mfg. Ramp for Advanced Biomaterial Products

FLORHAM PARK, N.J., April 08, 2024 (GLOBE NEWSWIRE) -- Celularity Inc. (NASDAQ: CELU) (“Celularity”), a biotechnology company developing placental-derived allogeneic cell therapies and advanced biomaterial products, announced today that it will present in vitro data from its investigational natural killer (NK) cell therapy programs at this year's American Society of Gene and Cell Therapy (ASGCT...

Nationally Established Q Code Will Further Support the Use of Biovance® 3L by Physicians to Treat Wound Care Patients in Office Settings Nationally Established Q Code Will Further Support the Use of Biovance® 3L by Physicians to Treat Wound Care Patients in Office Settings